The article provides an overview of analyst ratings for Allogene Therapeutics in the last quarter. While there are more bullish ratings than bearish or indifferent ones, the average 12-month price target has decreased by 27.8% from the previous average. This suggests that analysts have mixed opinions on the stock, which could lead to a neutral short-term impact on its price.